Rusfertide not checked

Protagonist Therapeutics, Inc. · TAK-121 · PTG-300

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
4 active
10 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Polycythemia Vera (4 trials)
Main trialPhase 3
“Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with…”In the company’s words, NCT05210790 on ClinicalTrials.gov
Other names
TAK-121 · PTG-300

Other drugs for Polycythemia Vera

All 18 drugs for Polycythemia Vera

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 21 Feb 2025 A Study of Rusfertide in Adults With Polycythemia Vera (PV)
Phase 3Active, not recruiting 1 Apr 2026 Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Phase 2Recruiting 28 Oct 2027 A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Phase 2Not yet recruiting 1 Jul 2028 A Study of Rusfertide in Adults With Polycythemia Vera in China
Phase 2Completed 31 Jul 2020 Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
Phase 2Completed 31 Jul 2020 Safety Study for Beta Thalassemia Subjects on PTG-300
Phase 2Completed 6 Oct 2021 PTG-300 in Subjects With Hereditary Hemochromatosis
Phase 2Completed 14 Feb 2023 Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Phase 2Completed 15 Mar 2023 PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Phase 1Completed 12 Jan 2021 Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rusfertide

Following is part of Solo: you see every change to Rusfertide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in